Neo Ivy Capital Management initiated a new position in American Healthcare REIT by purchasing 136,925 shares worth approximately $6.44 million. The REIT delivered strong 16.4% same-store NOI growth in Q3, driven by senior housing and integrated senior health campuses segments. Shares have surged 93% over the past year, with management raising full-year guidance.

Immunovant reported Q3 2025 financial results with a net loss of $110.6 million. The company's IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis is fully enrolled with topline data expected in H2 2026. A $550 million financing was completed in December 2025, extending cash runway through potential Graves' disease launch. Development remains on track across multiple indications including GD, MG, CIDP, and SjD.

Pulmovant has completed enrollment in its Phase 2 PHocus clinical trial evaluating mosliciguat for treating pulmonary hypertension associated with interstitial lung disease (PH-ILD) in under 12 months. The company remains on track to report topline results in the second half of 2026. Mosliciguat is a potential first-in-class, once-daily inhaled sGC activator designed to provide targeted pulmonary vasodilation with limited systemic side effects.

Sun Pharmaceutical Industries is reportedly evaluating a potential acquisition of Organon & Co, a U.S.-based women's healthcare company, in what could be India's largest cross-border pharma deal. Sun Pharma has submitted a non-binding all-cash bid with $10-14 billion in acquisition financing arranged. The deal, valued at approximately $10 billion including debt, would significantly strengthen Sun Pharma's presence in the U.S. market and women's health sector, though negotiations remain preliminary with no certainty of completion.

Roivant Sciences purchased 16.7 million shares of Immunovant for $350 million, increasing its ownership to 64.65% of outstanding shares. The biotech company focuses on monoclonal antibody therapies for autoimmune diseases and is currently in clinical trials for its lead drug candidate.

Roivant and Priovant reported successful Phase 3 clinical trial results for brepocitinib, demonstrating significant improvement in treating dermatomyositis, with plans to file for drug approval in 2026.

Imbria Pharmaceuticals appointed Dr. Pavan Cheruvu as Independent Board Chair and Dr. James Januzzi as Senior Research Advisor and Scientific Advisory Board Chair, signaling a new growth phase for the clinical-stage cardiovascular therapeutics company.

Pulmovant received orphan drug designation in Japan for mosliciguat, a potential treatment for Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), with ongoing Phase 2 clinical trials.

Immunovant presented promising six-month off-treatment data for batoclimab in Graves' disease, showing ~80% of patients maintained normal thyroid function and ~50% achieved anti-thyroid drug-free remission.

Moderna's stock has been struggling since the end of the COVID-19 pandemic, with a Wall Street analyst cutting her price target and reiterating a sell recommendation. The analyst cited issues such as cost-management struggles and legal headaches, as well as a hold on a late-stage trial for a norovirus vaccine candidate.

Organon has completed the acquisition of Dermavant Sciences, a company dedicated to developing and commercializing innovative therapeutic solutions in immuno-dermatology, including the FDA-approved VTAMA® (tapinarof) cream for the treatment of plaque psoriasis.

Roivant Sciences has agreed to sell its Dermavant Sciences subsidiary, which owns the rights to the psoriasis drug Vtama, to Organon for up to $1.2 billion. The transaction is expected to be modestly dilutive to Organon's Adjusted EBITDA in 2025 but turn accretive in 2026.